A Patented Medicine Prices Review Board Hearing Panel has issued an Order relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc. The Hearing Panel has issued a final Order that the redetermination proceeding be discontinued, based on a joint request by the parties. The final Order outlines the terms for the … Read more
The Patented Medicine Prices Review Board invites stakeholders to comment on its proposed approach for conducting interim price reviews while the PMPRB consults its stakeholders on new guidelines. The deadline to submit feedback is July 18, 2022. The full release is available online.
Two new reports released by the Patented Medicine Prices Review Board detail the current status of the market for new medicines in Canada, finding an uptick in the number of new medicines approved and a brimming drug pipeline. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
In response to the announcement made by Health Minister Jean-Yves Duclos (Québec, Que.) on April 14, regarding a change to regulatory amendments, the Patented Medicine Prices Review Board stated on April 22 that it will consult and develop a new set of guidelines. However, it will not be possible to finalize those guidelines by July … Read more
The Patented Medicine Prices Review Board will hold a public rehearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada. Further details on the public rehearing will be announced at a later date. Those … Read more
Health Minister Jean-Yves Duclos (Québec, Que.) tabled the 2020 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate. The 2020 Annual Report outlines the continuing rise in the sales of high-cost medicines in Canada. Sales of patented medicines grew to over $17.5 billion in 2020. … Read more
The Patented Medicine Prices Review Board released the third and final part in the Alignment Among Public Formularies in Canada series, which explores the current gaps and overlaps in Canadian public drug plan formularies. This report compares formulary coverage across Canada’s public drug plans for 307 medicines reviewed by the Canadian Agency for Drugs and Technologies in … Read more
The Government of Canada is seeking applicants for the Chairperson position on the Patented Medicine Prices Review Board by way of an open, transparent, and merit-based Governor in Council selection process. The full release is available online. Contact: PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
A new Patented Medicine Prices Review Board report finds that prescription drug expenditures by Canadian public drug plans increased by 3.7 per cent in 2019-20, bringing annual spending to $12.5 billion. The use of higher-cost medicines has been the primary factor behind rising costs for the public plans over the past five years, and this … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the second in a three part report series on Alignment Among Public Formularies in Canada. This latest report looks at gaps and overlaps in the coverage and funding of oncology drugs across Canada. The full release is available online.
